BC Innovations | Jun 19, 2014
Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) G protein-coupled receptor 109A (GPR109A; HM74A; HCAR2) Mouse studies suggest GPR109A activation is the mechanism of action for Tecfidera dimethyl fumarate...
BC Innovations | Dec 20, 2012
Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Tuberculosis G protein-coupled receptor 109A (GPR109A; HM74A) A study in macrophages and mice suggests inhibiting GPR109A could help treat tuberculosis....
BC Innovations | Mar 11, 2010
Distillery Therapeutics

Indication: Metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Metabolic disease Hypercholesterolemia; dyslipidemia G protein-coupled receptor 109A (GPR109A; HM74A) In vitro and in vivo studies identified niacin receptor agonists that could help reduce cholesterol levels...
BC Innovations | Apr 16, 2009
Distillery Therapeutics

Indication: Metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Metabolic disease Dyslipidemia Arrestin b1 (ARRB1); G protein-coupled receptor 109A (GPR109A; HM74A) In vitro and mouse studies suggest that GPR109A agonists that...
BC Innovations | Apr 2, 2009
Distillery Therapeutics

Indication: Metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Metabolic disease Hyperlipidemia G protein-coupled receptor 109A (NIACR1; GPR109A; HM74A); cytochrome P450 family 2 subfamily C polypeptide 8 (CYP2C8); CYP2C9 In vitro...
BC Week In Review | May 19, 2008
Clinical News

GPCR modulator: Phase I started

Taisho began a Phase I trial. The company has rights to the compound from Arena. Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif.   Taisho Pharmaceutical Co. Ltd. , Tokyo, Japan   Product: GPCR modulator   Business:...
BioCentury | Feb 18, 2008
Product Development

The weight loss imperative

While a recent study of obese Type II diabetes patients who received gastric banding surgery reinforces growing evidence that weight loss is the primary driver of diabetes remission in these patients, surgery itself is not...
BC Week In Review | Jan 14, 2008
Clinical News

INCB19602: Phase I data

In a Phase I trial in healthy volunteers, INCB19602 was well-tolerated and reduced free fatty acid levels without causing cutaneous flushing. Incyte Corp. (NASDAQ:INCY), Wilmington, Del.   Product: INCB19602   Business: Endocrine   Molecular target:...
BC Extra | Jan 9, 2008
Clinical News

Incyte gains after data presentations

Incyte (NASDAQ:INCY) gained $1.92 (20%) to $11.39 on Tuesday after reporting data from five clinical trials at the JPMorgan Healthcare Conference in San Francisco. Incyte presented data from three trials of INCB18424, including Phase IIa...
Items per page:
1 - 9 of 9